Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network

Clicks: 24
ID: 320988
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #98 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To assess the effectiveness of canakinumab (CAN) in controlling clinical and laboratory inflammation by achieving complete control of cardinal disease manifestations and full normalization of laboratory inflammatory markers. METHODS: Data were obtained from the international AutoInflammatory Disease Alliance (AIDA) network registry, dedicated to monogenic autoinflammatory diseases. The assessment included both retrospective and prospective real-world data. RESULTS: In total, 158 FMF patients treated with CAN were enrolled. Complete clinical-laboratory response was observed in 45.6% of patients at 3 months, 58.6% at 12 months, and 55.2% at the last follow-up, after a mean treatment duration of 45 months. Partial response occurred in 16.5%, 12.5%, and 16.8% at the same timepoints, respectively. Complete absence of clinical manifestations was observed in > 80% of patients at each timepoint. Inflammatory markers normalized significantly by the 3-month assessment. The probability of achieving and maintaining complete response and full laboratory control appeared higher in patients reaching these outcomes by 3 months, although it remained substantial in other patients as well. Complete response was associated with a relapsing-remitting disease course and fewer annual attacks. Nearly all patients maintained stable organ damage scores, and therapy discontinuation due to inefficacy was rare (≤6%). CONCLUSION: CAN is effective in achieving rapid and sustained clinical and laboratory control in FMF, including stringent endpoints of complete response. Early effectiveness may favour better long-term outcomes, but delayed achievement of complete response and full laboratory control is not uncommon. This study confirms CAN as an effective, and durable therapeutic option in FMF.
Reference Key
openalex_W7168284045 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Abdurrahman Tufan, Gaafar Ragab, Giuseppe Lopalco, Piero Portincasa, Donato Rigante, Sulaiman M Al-Mayouf, Ali Şahin, Nilüfer Tekgöz, Elena Verrecchia, Lampros Fotis, Patrizia Barone, Petros P Sfikakis, Ezgi Deniz Batu, Carla Gaggiano, Seza Ozen, Cemal Bes, Nergis Akay, Elif Kilic Konte, Ece Aslan, Zeynep Torunoglu, Burak Karakaya, Derya Yildirim, Hamit Kucuk, Antonino Noto, Mohamad Khalil, Ludovico Luca Sicignano, Alhanouf Alsaleem, Abdullah Alsonbul, Arif Babayiğit, Elmas Semanur, Katerina Kourtesi, Santi Papa, Katerina Laskari, Rabia Deniz, Annachiara Alemanno, Maria Cristina Maggio, José Hernández-Rodríguez, Veronica Gomez-Caverzaschi, Amato De Paulis, Ilaria Mormile, Emma Aragona, Fabrizio Bronte, Romina Gallizzi, Antonella Insalaco, Alma Nunzia Olivieri, Emre Bilgin, Nilay Erdik, Moustafa Ali Saad, Ángel Robles-Marhuenda, Alberto Lo Gullo, Alessandro Conforti, Fernando Tornero Romero, Benson Ogunjimi, Seher Sener, Micol Frassi, Giovanni Conti, Alberto Cauli, Marcello Govoni, Angelo Valerio Marzano, Chiara Moltrasio, Ewa Więsik-Szewczyk, Samar Tharwat, Abdelhafeez Moshrif, Anastasios Karamanakos, Alberto Balistreri, Bruno Frediani, Claudia Fabiani, Özgür Kasapçopur, Luca Cantarini
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag361
URL
https://doi.org/10.1093/rheumatology/keag361
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.